Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Cancer Research|March 2, 2018
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote SarcomagenesisShuai Ye, Matthew A Lawlor, Adrian Rivera-Reyes, et al.
Cancer Research|June 29, 2017
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of CancerJessie Hao-Ru Hsu, Benjamin Hubbell-Engler, Guillaume Adelmant, et al.
Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
Blood Advances|May 5, 2026
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemiaNastassja Keora Scheidegger, Constanze Schneider, Gabriela Alexe, et al.
Nature Communications|May 8, 2026
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trialsWallace Bourgeois, Hannah E Rice, Daniela V Wenge, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasTravis J Fleming, Mateusz Antoszewski, Sander Lambo, et al.
Blood|September 24, 2025
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasTravis J Fleming, Mateusz Antoszewski, Sander Lambo, et al.
Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.
Cancer Cell|December 11, 2019
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged LeukemiaAndrei V Krivtsov, Kathryn Evans, Jayant Y Gadrey, et al.
Pageof 7